According to Bristol-Myers Squibb's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.20032. At the end of 2023 the company had a P/S ratio of 2.32.
Year | P/S ratio | Change |
---|---|---|
2023 | 2.32 | -30% |
2022 | 3.31 | 11.08% |
2021 | 2.98 | -9.5% |
2020 | 3.30 | -39.73% |
2019 | 5.47 | 46.19% |
2018 | 3.74 | -22.49% |
2017 | 4.83 | -3.97% |
2016 | 5.03 | -27.14% |
2015 | 6.90 | 12.28% |
2014 | 6.15 | 15.44% |
2013 | 5.32 | 76.57% |
2012 | 3.01 | 7.25% |
2011 | 2.81 | 21.74% |
2010 | 2.31 | -10.66% |
2009 | 2.58 | 15.66% |
2008 | 2.23 | -21.96% |
2007 | 2.86 | -0.67% |
2006 | 2.88 | 23.12% |
2005 | 2.34 | -17.55% |
2004 | 2.84 | 7.6% |
2003 | 2.64 | 5.74% |
2002 | 2.50 | -52.16% |
2001 | 5.22 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 3.85 | 74.87% | ๐บ๐ธ USA |
Novartis NVS | 3.94 | 79.20% | ๐จ๐ญ Switzerland |
Pfizer PFE | 2.54 | 15.57% | ๐บ๐ธ USA |
AbbVie ABBV | 5.47 | 148.60% | ๐บ๐ธ USA |
Eli Lilly LLY | 20.4 | 827.17% | ๐บ๐ธ USA |
Amgen AMGN | 5.19 | 136.08% | ๐บ๐ธ USA |
Sanofi SNY | 2.31 | 5.01% | ๐ซ๐ท France |
Biogen BIIB | 2.99 | 35.67% | ๐บ๐ธ USA |
Merck MRK | 5.35 | 143.21% | ๐บ๐ธ USA |
AstraZeneca AZN | 4.82 | 119.00% | ๐ฌ๐ง UK |